[go: up one dir, main page]

AU2001233529A1 - Probiotic therapy for newborns - Google Patents

Probiotic therapy for newborns

Info

Publication number
AU2001233529A1
AU2001233529A1 AU2001233529A AU3352901A AU2001233529A1 AU 2001233529 A1 AU2001233529 A1 AU 2001233529A1 AU 2001233529 A AU2001233529 A AU 2001233529A AU 3352901 A AU3352901 A AU 3352901A AU 2001233529 A1 AU2001233529 A1 AU 2001233529A1
Authority
AU
Australia
Prior art keywords
newborns
probiotic therapy
probiotic
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233529A
Inventor
Andrew W. Bruce
Victor Han
Gregor Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001233529A1 publication Critical patent/AU2001233529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001233529A 2000-02-10 2001-02-09 Probiotic therapy for newborns Abandoned AU2001233529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18170200P 2000-02-10 2000-02-10
US60181702 2000-02-10
PCT/CA2001/000157 WO2001058465A2 (en) 2000-02-10 2001-02-09 Probiotic therapy for newborns

Publications (1)

Publication Number Publication Date
AU2001233529A1 true AU2001233529A1 (en) 2001-08-20

Family

ID=22665417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233529A Abandoned AU2001233529A1 (en) 2000-02-10 2001-02-09 Probiotic therapy for newborns

Country Status (3)

Country Link
US (1) US6613549B2 (en)
AU (1) AU2001233529A1 (en)
WO (1) WO2001058465A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
EP1264893A1 (en) * 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre CLA biosynthesis by bifidobacteria
GB0212975D0 (en) * 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
CA2820023A1 (en) * 2002-09-26 2007-12-19 Vita-Herb Nutriceuticals, Inc. Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
EP1624762B1 (en) * 2003-05-22 2007-02-28 Synbiotics AB A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
ITMI20032391A1 (en) * 2003-12-05 2005-06-06 Consiglio Nazionale Ricerche MENSA OLIVES CONTAINING PROBIOTIC MICRO-ORGANISMS.
WO2005089564A1 (en) 2004-03-19 2005-09-29 Danisco A/S Emulsifier composition for shortening
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
TWI362949B (en) * 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US20080107699A1 (en) * 2006-10-25 2008-05-08 Mark Spigelman Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor
DE502007004849D1 (en) 2007-02-02 2010-10-07 May Amadeus Alexander Product with live probiotic microorganisms
ES2381232T3 (en) * 2007-02-28 2012-05-24 Mead Johnson Nutrition Company Procedure for the treatment or prevention of systemic inflammation
AU2008230747A1 (en) * 2007-03-27 2008-10-02 The Procter & Gamble Company Methods and kits for administering probiotics
WO2009047537A1 (en) * 2007-10-11 2009-04-16 Fayrefield Foods Limited Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material
EP2348890B1 (en) 2008-03-28 2013-09-18 Nestec S.A. Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010063601A1 (en) * 2008-12-05 2010-06-10 Nestec S.A. Compositions for use in low-birth weight infants
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
FI20096402A0 (en) * 2009-12-28 2009-12-28 Suomen Punainen Risti Veripalv Use of blood group status II
FI20096400A0 (en) * 2009-12-28 2009-12-28 Suomen Punainen Risti Veripalv Use of blood group status I
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
EP2394920A1 (en) * 2010-06-14 2011-12-14 Nestec S.A. Dispensing container for probiotics
PT3628161T (en) 2012-11-23 2023-05-15 Seres Therapeutics Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
JP6479685B2 (en) 2013-02-04 2019-03-06 セレス セラピューティクス インコーポレイテッド Compositions and methods for the control of pathogenic bacterial growth
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
ES3017865T3 (en) 2013-11-25 2025-05-13 Nestle Sa Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US20180104157A1 (en) * 2015-04-17 2018-04-19 Evolve Biosystems, Inc. Delivering non-pathogenic, intestinally beneficial bacteria to a patient having a feeding tube
JP2020530840A (en) 2017-08-14 2020-10-29 セレス セラピューティクス インコーポレイテッド Compositions and Methods for Treating Cholestasis Diseases
RU2020117775A (en) 2017-10-30 2021-12-01 Серес Терапеутикс, Инк. COMPOSITIONS AND METHODS FOR TREATMENT OF ANTIBIOTIC RESISTANCE
TWI718402B (en) * 2018-08-16 2021-02-11 葡萄王生技股份有限公司 An active substance of lactobacillus paracasei gks6, a composition comprising thereof and its use for promoting longevity
US11524098B2 (en) * 2018-09-14 2022-12-13 Avent, Inc. Systems and methods for biofilm inoculation
EP4032536A1 (en) 2021-01-26 2022-07-27 Probisearch, S.L.U. Probiotic composition for infants and its uses
CN116676214B (en) * 2023-04-28 2025-08-22 中国农业大学 Lactobacillus delbrueckii and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984575A (en) * 1974-02-06 1976-10-05 Microlife Technics, Inc. Bacterial compositions for changing the digestive system bacteria in animals
SU1743607A1 (en) * 1990-02-05 1992-06-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Method for prevention of intestinal dysbacteriosis in newborn infants
NZ287420A (en) 1994-05-26 1997-12-19 Bracco Spa Lactobacillus strains with enhanced gut adhesion
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
AU4905300A (en) 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women

Also Published As

Publication number Publication date
WO2001058465A3 (en) 2002-04-25
US20010036453A1 (en) 2001-11-01
US6613549B2 (en) 2003-09-02
WO2001058465A2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AU2001233529A1 (en) Probiotic therapy for newborns
AUPQ899700A0 (en) Probiotic recolonisation therapy
AU2001252135A1 (en) Therapeutic agents
AU2001275921A1 (en) Pulmonary therapy apparatus
AU2001234846A1 (en) Integrated resuscitation
AU2001245792A1 (en) Proning bed
GB0028429D0 (en) Therapy
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU7882900A (en) Hydrotherapy bed
AU2001238488A1 (en) Human kinases
AU2002332074A1 (en) Padded absorbent article
AU2001234178A1 (en) Modified bdnf
AU2002227925A1 (en) Human beta-defensin-3
AU2001270129A1 (en) Human phosphodiesterases
AU2002335667A1 (en) Modified reoviral therapy
AU2001273903A1 (en) Therapeutic agents
AU2001286341A1 (en) Therapeutic bio-energy unit
AU2001255573A1 (en) Human kinases
AU2001275696A1 (en) Therapeutic agent
AU2001292897A1 (en) Novel therapy
WO2001085090A8 (en) Therapy device
AU2001260789A1 (en) Wheelchair
AU3447900A (en) Assay for therapy
AU4060401A (en) Massaging armchairs
AU2001252445A1 (en) Sanitary bed